Skip to main content

ALEC

Stock
Health Care
Biotechnology

Performance overview

ALEC Price
Price Chart

Forward-looking statistics

Beta
1.85
Risk
81.92%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

we are a biotech company based in san francisco dedicated to the discovery and development of novel therapies harnessing the power of immune system to treat neurodegenerative diseases such as alzheimer's disease.

Company info

SectorHealth Care
IndustryBiotechnology
Employees269
Market cap$420.2M

Fundamentals

Enterprise value-$173.5M
Revenue$88.3M
Revenue per employee
Profit margin-139.74%
Debt to equity43.39

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$1.26
Dividend per share
Revenue per share$0.90
Avg trading volume (30 day)$984K
Avg trading volume (10 day)$869K
Put-call ratio

Macro factor sensitivity

Growth-2.4
Credit+6.6
Liquidity+2.4
Inflation-7.6
Commodities-1.1
Interest Rates-1.4

Valuation

Dividend yield0.00%
PEG Ratio-1.02
Price to sales1.71
P/E Ratio-1.02
Enterprise Value to Revenue-1.96
Price to book1.60

Upcoming events

Next earnings dayMay 9, 2025
Next dividend day
Ex. dividend day

News

Alector (ALEC) Reports Q4 Loss, Tops Revenue Estimates

Alector (ALEC) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to loss of $0.49 per share a year ago.

Zacks Investment Research (February 26, 2025)
Neurology-Focused Alector Downgraded On Failed Alzheimer's Study, BofA Securities Highlights Lack Of Catalysts

Bank of America Securities has downgraded Alector, Inc.  ALEC, citing the failure of its AL002 program.

Benzinga (December 4, 2024)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free